These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 39112628

  • 1. One versus 2 years of alendronate following denosumab: the CARD extension.
    Tsai JN, Jordan M, Lee H, Leder BZ.
    Osteoporos Int; 2024 Aug 07. PubMed ID: 39112628
    [Abstract] [Full Text] [Related]

  • 2. The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.
    Ramchand SK, Tsai JN, Lee H, Sassana-Khadka G, Jordan M, Ryan S, Leder BZ.
    Osteoporos Int; 2024 Feb 07; 35(2):255-263. PubMed ID: 37798320
    [Abstract] [Full Text] [Related]

  • 3. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.
    J Bone Miner Res; 2010 Jan 07; 25(1):72-81. PubMed ID: 19594293
    [Abstract] [Full Text] [Related]

  • 4. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 07; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 5. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
    Michalská D, Stepan JJ, Basson BR, Pavo I.
    J Clin Endocrinol Metab; 2006 Mar 07; 91(3):870-7. PubMed ID: 16352692
    [Abstract] [Full Text] [Related]

  • 6. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 07; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 7. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.
    Bone; 2014 Jan 07; 58():48-54. PubMed ID: 24141036
    [Abstract] [Full Text] [Related]

  • 8. Treatment for osteoporosis in people with beta-thalassaemia.
    Bhardwaj A, Swe KMM, Sinha NK.
    Cochrane Database Syst Rev; 2023 May 09; 5(5):CD010429. PubMed ID: 37159055
    [Abstract] [Full Text] [Related]

  • 9. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.
    Mok CC, Ho LY, Leung SMT, Cheung HN, Chen SPL, Ma KM.
    Bone; 2021 May 09; 146():115902. PubMed ID: 33631355
    [Abstract] [Full Text] [Related]

  • 10. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE, Fosamax Actonel Comparison Trial investigators.
    Curr Med Res Opin; 2004 Dec 09; 20(12):2031-41. PubMed ID: 15706659
    [Abstract] [Full Text] [Related]

  • 11. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ, Tsai JN, Jiang LA, Lee H.
    Bone; 2017 May 09; 98():54-58. PubMed ID: 28286299
    [Abstract] [Full Text] [Related]

  • 12. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul 09; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 13. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
    McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A.
    J Bone Miner Res; 2018 Aug 09; 33(8):1397-1406. PubMed ID: 29694685
    [Abstract] [Full Text] [Related]

  • 14. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H.
    J Bone Miner Res; 2014 Aug 09; 29(8):1777-85. PubMed ID: 24619763
    [Abstract] [Full Text] [Related]

  • 15. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
    Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J.
    Bone; 2008 Aug 09; 43(2):222-229. PubMed ID: 18539106
    [Abstract] [Full Text] [Related]

  • 16. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
    Bønløkke SE, Rand MS, Haddock B, Arup S, Smith CD, Jensen JEB, Schwarz P, Hovind P, Oturai PS, Jensen LT, Møller S, Eiken P, Rubin KH, Hitz MF, Abrahamsen B, Jørgensen NR.
    Osteoporos Int; 2022 Oct 09; 33(10):2155-2164. PubMed ID: 35729342
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension.
    Ramchand SK, David NL, Lee H, Eastell R, Tsai JN, Leder BZ.
    J Bone Miner Res; 2021 May 09; 36(5):921-930. PubMed ID: 33507574
    [Abstract] [Full Text] [Related]

  • 18. Skeletal responses to romosozumab after 12 months of denosumab.
    McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Shi Y, Timoshanko J, Libanati C, Chines A, Oates MK.
    JBMR Plus; 2021 Jul 09; 5(7):e10512. PubMed ID: 34258507
    [Abstract] [Full Text] [Related]

  • 19. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study.
    Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ.
    Bone; 2017 Feb 09; 95():20-25. PubMed ID: 27840301
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
    Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG.
    J Bone Miner Res; 2009 Jan 09; 24(1):153-61. PubMed ID: 18767928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.